KR20260016503A - 암성 동통 예방 또는 치료용 조성물 - Google Patents

암성 동통 예방 또는 치료용 조성물

Info

Publication number
KR20260016503A
KR20260016503A KR1020257041808A KR20257041808A KR20260016503A KR 20260016503 A KR20260016503 A KR 20260016503A KR 1020257041808 A KR1020257041808 A KR 1020257041808A KR 20257041808 A KR20257041808 A KR 20257041808A KR 20260016503 A KR20260016503 A KR 20260016503A
Authority
KR
South Korea
Prior art keywords
substituted
halogen atoms
group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257041808A
Other languages
English (en)
Korean (ko)
Inventor
에리카 구보
요시로 야마무라
쇼이치 시마다
유키코 야마모토
Original Assignee
마루이시세이야쿠가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마루이시세이야쿠가부시키가이샤 filed Critical 마루이시세이야쿠가부시키가이샤
Publication of KR20260016503A publication Critical patent/KR20260016503A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257041808A 2023-05-25 2024-05-23 암성 동통 예방 또는 치료용 조성물 Pending KR20260016503A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2023-086153 2023-05-25
JP2023086153 2023-05-25
PCT/JP2024/018940 WO2024242158A1 (ja) 2023-05-25 2024-05-23 がん性疼痛予防又は治療用組成物

Publications (1)

Publication Number Publication Date
KR20260016503A true KR20260016503A (ko) 2026-02-03

Family

ID=93589461

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257041808A Pending KR20260016503A (ko) 2023-05-25 2024-05-23 암성 동통 예방 또는 치료용 조성물

Country Status (9)

Country Link
EP (1) EP4699608A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024242158A1 (cg-RX-API-DMAC7.html)
KR (1) KR20260016503A (cg-RX-API-DMAC7.html)
CN (1) CN121079089A (cg-RX-API-DMAC7.html)
AU (1) AU2024275598A1 (cg-RX-API-DMAC7.html)
IL (1) IL324153A (cg-RX-API-DMAC7.html)
MX (1) MX2025013810A (cg-RX-API-DMAC7.html)
TW (1) TW202508584A (cg-RX-API-DMAC7.html)
WO (1) WO2024242158A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5636481A (en) 1979-06-21 1981-04-09 Clin Midy Aminopiperidine* its manufacture* intermediate and medicine
JPH07145166A (ja) 1991-03-27 1995-06-06 Sanofi Sa 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用
JP7090344B2 (ja) 2017-06-28 2022-06-24 国立大学法人大阪大学 セロトニン3受容体アゴニストによる疼痛の治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5636481A (en) 1979-06-21 1981-04-09 Clin Midy Aminopiperidine* its manufacture* intermediate and medicine
JPH07145166A (ja) 1991-03-27 1995-06-06 Sanofi Sa 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用
JP7090344B2 (ja) 2017-06-28 2022-06-24 国立大学法人大阪大学 セロトニン3受容体アゴニストによる疼痛の治療

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Janette Nallely Corona-Ramos et al, The effect of Gabapentin and Tramadol in Cancer Pain Induced by Glioma Cell in Rat Femur, Drug Development Research, 2017년, 제78권, 173-183페이지
Mohammad Zafar Imam et al, Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain, Pharmacological Reports, 2020년 7월 26일, 제72권, 1418-1425페이지
Mohammed El Mouedden et al, Pharmacological evaluation of opioid and non-opioid analgesis in a murine bone cancer model of pain, Pharmacology, Biochemistry and Behavior, 2007년 1월 12일, 제86권, 458-467페이지
Osamu Saito et al, Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain, Journal of Anesthesia, 2005년, 제19권, 218-224페이지
Simeng Ma et al, Amitriptyline influences the mechanical withdrawal threshold in bone cancer pain rats by regulating glutamate transporter GLAST, Molecular Pain, 2019년, 제15권, 1-12페이지
Tansy Donovan-Rodriguez et al, Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-induced Bone Pain, Anesthesiology, 2005년, 제102권, 132-140페이지
기타노 유타카(北野裕) 등, 일본약리지, 2019년, 제154권, 352-361페이지
바아트리스제약가부시키가이샤, 리리카(등록상표) 캡슐 및 OD정의 25mg, 75mg 및 150mg의 첨부 문서, 2022년 7월 개정(제3판)
의료용마약 적정사용가이던스 후생노동성 의약·생활 위생국 감시지도·마약대책과 2017년 4월

Also Published As

Publication number Publication date
TW202508584A (zh) 2025-03-01
EP4699608A1 (en) 2026-02-25
AU2024275598A1 (en) 2026-01-15
CN121079089A (zh) 2025-12-05
WO2024242158A1 (ja) 2024-11-28
MX2025013810A (es) 2025-12-01
IL324153A (en) 2025-12-01
JPWO2024242158A1 (cg-RX-API-DMAC7.html) 2024-11-28

Similar Documents

Publication Publication Date Title
US10952976B2 (en) Compositions and methods for treating respiratory depression with fenfluramine
US8653033B2 (en) Method for administering omega-conopeptide
KR102489052B1 (ko) 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
JP2005522445A (ja) 注意欠陥過活動性障害(ad/hd)の処置方法
CN117177772A (zh) 伴有饥饿素抵抗性的恶病质的治疗剂或预防剂
WO2024242158A1 (ja) がん性疼痛予防又は治療用組成物
WO2007040535A1 (en) Use of polyamine analogs for treatment and prevention of intestinal polyps
CN103002893A (zh) 神经障碍性疼痛的治疗药或预防药
CA3289710A1 (en) Composition for preventing or treating cancer pain
JP7090344B2 (ja) セロトニン3受容体アゴニストによる疼痛の治療
EP3087984B1 (en) Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
US20220024976A1 (en) Salt and crystalline forms of rapastinel
KR101779135B1 (ko) 덱사메타손과 이부프로펜을 유효성분으로 포함하는 신경병증성 통증 예방 및 치료용 약학적 조성물
JPWO2005089742A1 (ja) 頻尿または尿失禁の予防または治療用医薬
JP2005314313A (ja) 過敏性腸症候群を予防又は治療するための医薬

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)